Claude Waddington’s Post

View profile for Claude Waddington

LinkedIn Top Leadership Voice in Pharma Digital Strategy

Salesforce and IBM have announced Zero Copy Integration between IBM Z and Salesforce Data Cloud. This isn’t just infrastructure news. It’s a glimpse of how the intelligence layer in pharma and medtech will be rewired. In plain terms: mission-critical data, previously locked away on mainframes, can now be activated in Salesforce without duplication, delay, or migration. That means a 360° patient or HCP view, sharper AI models, and real-time decisioning inside Health Cloud. Why this matters for pharma and medtech? Healthcare runs on data gravity. Clinical trial records, supply chain transactions, pharmacovigilance logs, real-world evidence, and market access contracts. Much of it still sits in complex, siloed legacy systems. Historically, getting that data into a CRM or engagement layer meant slow, brittle ETL pipelines. Now, with Zero Copy, Salesforce can tap IBM Z data streams directly, while IBM watsonx provides the AI horsepower to make sense of it. For pharma, this unlocks new use cases: 1. Hyper-personalised HCP engagement with data flowing seamlessly into Salesforce Health Cloud. 2. Real-time issue resolution — surfacing shipment delays, stockouts, or adverse event signals directly in service consoles. 3. Lifecycle management and compliance — using mainframe transaction data to identify renewals, flag fraud, or manage regulatory risk without moving sensitive data. Here's the bigger picture. This is not about incremental efficiency. It’s about designing the foundations for agentic AI in healthcare: intelligent agents that can orchestrate engagement, service, and compliance in real-time, powered by secure, federated data. For pharma and medtech leaders, the challenge is no longer if Health Cloud can become the engagement OS — it’s how quickly your enterprise can re-platform around this new intelligence layer. Chugai Pharmaceutical Co., Ltd., Pfizer, The Janssen Pharmaceutical Companies of Johnson & Johnson, Moderna, Fresenius Kabil, MENARINI Group, Sanofi, Amgen, Bayer, Kite Pharma, and Boehringer Ingelheim already leverage Salesforce and they are set to further scale ops. Our take at The Palindromic is that this partnership signals a reshaping of healthcare’s data operating system. Veeva Systems, IQVIA, Salesforce, and now IBM are all positioning to be the indispensable layer between data and decision. The winners in pharma will be those who act early, piloting zero-copy architectures, embedding AI agents, and re-engineering workflows around real-time intelligence. If you need help with mapping your next steps, we're here to help - and we speak pharma and tech! Thanks Mary Fratto Rowe for flagging this up. Frank Defesche this is an interesting move, keen to see how this ties into the partnership with Bernd Haas. Kuber Sharma + Narinder Singh from Salesforce (both former Microsoft), and Anson Kokkat from IBM, will have a webinar on this topic next week. #watsonx #SalesforceHealthCloud #AIagents #AgenticAI #AIinHealthcare

Guillermo López Zarrabeitia

International IT Associate Director | AI & Innovation Strategist | Pharma Expertise | Digital Strategy | CRM | Product Experience & Business Model Improvement | Vendor Management

1mo

Claude Waddington Thanks for sharing this insightful article. Without a doubt, the moves by both, Salesforce and Veeva, are not aimed at reshaping an already established CRM product, but rather at building the bridges toward Agentic AI and making CRM systems smarter. Customer360 is dead, long life Customer AI!

To view or add a comment, sign in

Explore content categories